Venus Remedies' oncology wing has also secured marketing authorisation from Myanmar for another chemotherapy drug
NexCAR19 is an indigenously developed CD19 targeted CAR-T cell therapy
BioNTech's diverse pipeline includes multiple drugs in Phase I, II, and III clinical trials
KEYTRUDA is the first immunotherapy approved in the EU for the first-line treatment of this patient population
Deep Transcranial Magnetic Stimulation (dTMS) is a non-invasive brain stimulation technique approved by regulatory authorities, including the USFDA
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Jemperli is the only immuno-oncology treatment approved in the frontline setting for this patient population in combination with chemotherapy
If approved, KEYTRUDA would be the first immunotherapy for the first-line treatment of HER2-positive advanced gastric or GEJ cancer in tumors expressing PD-L1 (CPS ?1) in the EU
Mage Biologics to develop a monoclonal antibody targeting ulcerative colitis
Approval to dramatically change CAR-T therapies landscape
Subscribe To Our Newsletter & Stay Updated
